Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$41.71|
|52 Week High||AU$19.63|
|52 Week Low||AU$42.20|
|1 Month Change||45.13%|
|3 Month Change||43.04%|
|1 Year Change||82.30%|
|3 Year Change||120.22%|
|5 Year Change||583.77%|
|Change since IPO||4,071.00%|
Recent News & Updates
Here's Why I Think Clinuvel Pharmaceuticals (ASX:CUV) Might Deserve Your Attention Today
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
|CUV||AU Biotechs||AU Market|
Return vs Industry: CUV exceeded the Australian Biotechs industry which returned 10.4% over the past year.
Return vs Market: CUV exceeded the Australian Market which returned 27% over the past year.
Stable Share Price: CUV is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: CUV's weekly volatility (8%) has been stable over the past year.
About the Company
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide.
Clinuvel Pharmaceuticals Fundamentals Summary
|CUV fundamental statistics|
Is CUV overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CUV income statement (TTM)|
|Cost of Revenue||AU$6.78m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.50|
|Net Profit Margin||51.54%|
How did CUV perform over the long term?See historical performance and comparison
0.06%Current Dividend Yield
Is Clinuvel Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CUV (A$41.71) is trading below our estimate of fair value (A$42.52)
Significantly Below Fair Value: CUV is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: CUV is poor value based on its PE Ratio (83.3x) compared to the Global Biotechs industry average (35.3x).
PE vs Market: CUV is poor value based on its PE Ratio (83.3x) compared to the Australian market (18.7x).
Price to Earnings Growth Ratio
PEG Ratio: CUV is poor value based on its PEG Ratio (2.6x)
Price to Book Ratio
PB vs Industry: CUV is overvalued based on its PB Ratio (20.9x) compared to the AU Biotechs industry average (4.9x).
How is Clinuvel Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CUV's forecast earnings growth (32% per year) is above the savings rate (1.9%).
Earnings vs Market: CUV's earnings (32% per year) are forecast to grow faster than the Australian market (11.5% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: CUV's revenue (31.6% per year) is forecast to grow faster than the Australian market (5.3% per year).
High Growth Revenue: CUV's revenue (31.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CUV's Return on Equity is forecast to be high in 3 years time (29.9%)
How has Clinuvel Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CUV has a high level of non-cash earnings.
Growing Profit Margin: CUV's current net profit margins (51.5%) are higher than last year (46.2%).
Past Earnings Growth Analysis
Earnings Trend: CUV has become profitable over the past 5 years, growing earnings by 36.5% per year.
Accelerating Growth: CUV's earnings growth over the past year (64.3%) exceeds its 5-year average (36.5% per year).
Earnings vs Industry: CUV earnings growth over the past year (64.3%) exceeded the Biotechs industry 41.5%.
Return on Equity
High ROE: CUV's Return on Equity (25%) is considered high.
How is Clinuvel Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: CUV's short term assets (A$102.8M) exceed its short term liabilities (A$8.7M).
Long Term Liabilities: CUV's short term assets (A$102.8M) exceed its long term liabilities (A$1.1M).
Debt to Equity History and Analysis
Debt Level: CUV is debt free.
Reducing Debt: CUV has not had any debt for past 5 years.
Debt Coverage: CUV has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CUV has no debt, therefore coverage of interest payments is not a concern.
What is Clinuvel Pharmaceuticals's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: CUV's dividend (0.06%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.3%).
High Dividend: CUV's dividend (0.06%) is low compared to the top 25% of dividend payers in the Australian market (5.41%).
Stability and Growth of Payments
Stable Dividend: CUV is not paying a notable dividend for the Australian market, therefore no need to check if payments are stable.
Growing Dividend: CUV is not paying a notable dividend for the Australian market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: CUV is not paying a notable dividend for the Australian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CUV's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Philippe Wolgen (58 yo)
Dr. Philippe Jacques Wolgen, MBA, M.D., has been the Chief Executive Officer and Managing Director of Clinuvel Pharmaceuticals Limited since November 28, 2005 to lead the corporate turnaround of the Group....
CEO Compensation Analysis
Compensation vs Market: Philippe's total compensation ($USD1.94M) is above average for companies of similar size in the Australian market ($USD1.28M).
Compensation vs Earnings: Philippe's compensation has been consistent with company performance over the past year.
Experienced Management: CUV's management team is seasoned and experienced (15.7 years average tenure).
Experienced Board: CUV's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CUV insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Clinuvel Pharmaceuticals Limited's employee growth, exchange listings and data sources
- Name: Clinuvel Pharmaceuticals Limited
- Ticker: CUV
- Exchange: ASX
- Founded: 1987
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$2.061b
- Shares outstanding: 49.41m
- Website: https://www.clinuvel.com
- Clinuvel Pharmaceuticals Limited
- 535 Bourke Street
- Level 11
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/18 08:03|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.